Aug 21 (Reuters) - Bavarian Nordic ( BVNKF ) said on

Wednesday that it has received a contract to supply 440,000

doses of smallpox and mpox vaccines to an undisclosed European

country.

The Danish biotech firm said the latest order was

anticipated as part of its outlook for the year, and will not

impact the remaining capacity that is available to support

governments and organizations to address the current emergency.

Last week, the World Health Organization declared that

an outbreak of mpox, a viral infection that spreads through

close contact, represents a global health emergency for the

second time in two years.

"Bavarian Nordic ( BVNKF ) can still supply up to 10 million doses

of our smallpox and mpox vaccine by the end of next year, with 2

million doses of this capacity available during the remaining

part of this year," said CEO Paul Chaplin.

The company could ramp up production of its mpox vaccine

even before having orders lined up, based on the outcome of

talks this week with the WHO, Chaplin told Reuters on Tuesday.